"Profitability comes from low-cost manufacturing," says Jean-Michel Halfon, Pfizer president for emerging markets. "Low-cost solutions developed in emerging markets could be useful everywhere. We're working on it." Article
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments